In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer

BACKGROUND: Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that has been investigated as a potential chemopreventive and chemotherapeutic agent. However, the antitumor efficacy and mechanisms of TGZ in pancreatic cancer have not been extensively investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Megumi, Hasegawa, Ai, Yamamori, Motohiro, Okamura, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496133/
https://www.ncbi.nlm.nih.gov/pubmed/28673319
http://dx.doi.org/10.1186/s13046-017-0557-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496133/
https://www.ncbi.nlm.nih.gov/pubmed/28673319
http://dx.doi.org/10.1186/s13046-017-0557-6

Ejemplares similares